Analyst rates Rocket Pharmaceuticals a Hold: KRESLADI onboarding and cardiovascular validation must advance before a bullish view; shares trade at 0.71x...
Rocket Pharmaceuticals charts pivotal Phase 2 path for Danon disease gene therapy RP-A501. Read more here.
CRANBURY, N.J., October 06, 2026--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders, today announced that it has entered into a credit facility agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $150 million. The facility strengthens Rocket’s financial position and provides access to additional capital to support executi
Rocket Pharmaceuticals (RCKT) stock gains as Needham upgrades the company to Buy after FDA alignment on a pivotal Phase 2 trial for a Danon disease.drug. Read more here.
Rocket Pharmaceuticals aligns with the FDA on key phase II study elements for RP-A501, advancing its Danon disease gene therapy program toward completion.
Needham said the FDA outcome was better than expected because the regulator could have demanded meaningful changes to Rocket’s Danon disease trial.
The FDA confirmed continued enrollment and dosing under the modified trial protocol after reviewing safety data from the first three patients treated at the recalibrated dose.
This is the newest page. Registered accounts read further back.